Combined use of neuroradiology and 1H‐MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme

To evaluate the accuracy of 1H‐MR spectroscopy (1H‐MRS) as an intervention limiting diagnostic tool for glioblastoma multiforme. GBM is the most common and aggressive primary brain tumor, with mean survival under a year. Oncological practice currently requires histopathological diagnosis before radiotherapy.

[1]  A R Tate,et al.  The contribution of proton magnetic resonance spectroscopy ( 1 HMRS) to clinical brain tumour diagnosis , 2002, British journal of neurosurgery.

[2]  Carles Arús,et al.  Automated quality control protocol for MR spectra of brain tumors , 2008, Magnetic resonance in medicine.

[3]  M. Bernstein,et al.  Failed stereotactic biopsy in a series of 518 cases. , 1995, Stereotactic and functional neurosurgery.

[4]  Franklyn A Howe,et al.  1H MR spectroscopy of brain tumours and masses , 2003, NMR in biomedicine.

[5]  Margarida Julià-Sapé,et al.  Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. , 2004, AJNR. American journal of neuroradiology.

[6]  R. Lenkinski,et al.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. , 2006, AJNR. American journal of neuroradiology.

[7]  Carles Arús,et al.  Automated classification of short echo time in in vivo 1H brain tumor spectra: A multicenter study , 2003, Magnetic resonance in medicine.

[8]  F. Ansfield.  Present status of clinical cancer chemotherapy. , 1965, Antimicrobial agents and chemotherapy.

[9]  M. Weller.  Glucocorticoid Treatment of Primary CNS Lymphoma , 1999, Journal of Neuro-Oncology.

[10]  I. Whittle,et al.  How well do radiologists diagnose intracerebral tumour histology on CT? Findings from a prospective multicentre study , 2002, British journal of neurosurgery.

[11]  A. W. Simonetti,et al.  Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra , 2006, NMR in biomedicine.

[12]  H. Lanfermann,et al.  Diagnostic impact of proton MR-spectroscopy versus image-guided stereotactic biopsy , 2007, Acta Neurochirurgica.

[13]  D. Vigneron,et al.  An automated technique for the quantitative assessment of 3D‐MRSI data from patients with glioma , 2001, Journal of magnetic resonance imaging : JMRI.

[14]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[15]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[16]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[17]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[18]  J R Griffiths,et al.  Linear discriminant analysis of brain tumour 1H MR spectra: a comparison of classification using whole spectra versus metabolite quantification , 2007, NMR in biomedicine.

[19]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Warnke,et al.  Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. , 1993, Journal of neurosurgery.

[21]  S. Bluml,et al.  Efficacy of Proton Magnetic Resonance Spectroscopy Inclinical Decision Making for Patients with Suspected Malignant Brain Tumors , 2004, Journal of Neuro-Oncology.

[22]  Arend Heerschap,et al.  Combination of feature‐reduced MR spectroscopic and MR imaging data for improved brain tumor classification , 2005, NMR in biomedicine.

[23]  A. M. Mishra,et al.  The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. , 2006, Surgical neurology.

[24]  M. Bernstein,et al.  Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. , 1994, Journal of neurosurgery.

[25]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[26]  N. Ferreira,et al.  Stereotactic computed tomography-guided brain biopsy: diagnostic yield based on a series of 170 patients. , 2006, Surgical neurology.

[27]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[28]  H. Lanfermann,et al.  Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions , 2002, Neuroradiology.